Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Complete Title: Phase 1/1b study evaluating safety and efficacy of PRGN-3005 (autologous CAR T cells) in advance stage platinum resistant ovarian cancer patients
Trial Phase: I
Investigator: John Liao
This is a phase I dose escalation study to identify the best dose and side effects of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back, and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.
Keywords:
- Ovarian Cancer
- Neoplasms
- Urogenital Neoplasms
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Carcinoma
- Endocrine Gland Neoplasms
- Pathologic Processes
- Gonadal Disorders
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
John Liao
RG1004303
NCT03907527
Phase 1/1b study evaluating safety and efficacy of PRGN-3005 (autologous CAR T cells) in advance stage platinum resistant ovarian cancer patients
Ovarian Cancer
Neoplasms
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Genital Neoplasms, Female
Carcinoma
Endocrine Gland Neoplasms
Pathologic Processes
Gonadal Disorders